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Abstract 
Mutations in the skeletal muscle ryanodine receptor (RYR1) gene are associated with a wide 
spectrum of inherited myopathies presenting throughout life. Malignant Hyperthermia Susceptibility 
(MHS)-related RYR1 mutations have emerged as a common cause of exertional rhabdomyolysis, 
accounting for up to 30% of rhabdomyolysis episodes in otherwise healthy individuals. Common 
triggers are exercise and heat and, less frequently, viral infections, alcohol and drugs. Most subjects 
are normally strong and have no personal or family history of malignant hyperthermia. Heat 
intolerance and cold-induced muscle stiffness may be a feature. Recognition of this (probably not 
uncommon) rhabdomyolysis cause is vital for effective counselling, to identify potentially malignant 
hyperthermia-susceptible individuals and to adapt training regimes. Studies in various animal models 
provide insights regarding possible pathophysiological mechanisms and offer therapeutic 
perspectives. 
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1. Introduction 
Mutations in the skeletal muscle ryanodine receptor (RYR1) gene are associated with a wide 
spectrum of inherited myopathies presenting throughout life [1], including dominantly inherited 
Central Core Disease (CCD) [2], and subgroups of recessively inherited Multi-minicore Disease (MmD) 
[3], Centronuclear Myopathy (CNM) [4] and Congenital Fibre Type Disproportion (CFTD) [5]. The 
dominantly inherited Malignant Hyperthermia Susceptibility (MHS) trait, a pharmacogenetic 
predisposition to severe and potentially life-threatening reactions in response to volatile 
anaesthetics and succinylcholine (for review, [6]), is an allelic condition; some patients with CCD may 
also be MH-susceptible, and MH-susceptible individuals may feature cores on muscle biopsy even 
without being weak. 
The majority of MH-susceptible individuals are clinically asymptomatic unless exposed to triggering 
agents, however, several permanent or induced muscular manifestations appear to be specifically 
associated with MHS-related RYR1 mutations: King-Denborough syndrome (KDS) is an early-onset 
myopathy with short stature, scoliosis, dysmorphic features and a predisposition to MH reactions [7]. 
More recently, (MHS-related) RYR1 mutations have also emerged as a common cause of exertional 
rhabdomyolysis (ERM), accounting for up to 30% of rhabdomyolysis (RM) episodes in otherwise 
healthy individuals [8]. This review will focus on the features of RYR1-related (E)RM by discussing the 
key features from cases reported to date, summarizing the proposed pathophysiological 
mechanism(s) extrapolated from observations in relevant animal models, and suggesting how this 
probably not uncommon manifestation of RYR1 mutations can be recognized and how it should be 
managed. 
 
2. (Exertional) rhabdomyolysis  
RM (from the Greek, literally the “dissolution of striated muscle”) is the general term for muscle 
breakdown associated with a wide variety of external triggers, including strenuous exercise beyond 
the limit of fatigue, inadequate hydration, high ambient temperatures, use of supplements (ephedra, 
creatine, and herbal weight loss supplements) or certain medications (statins, selective serotonin 
reuptake inhibitors), illicit drug or alcohol abuse, muscle trauma, or recent viral illnesses. Although 
there is no universally accepted definition, RM is often defined as a clinical syndrome associated with 
severe muscle pain, sudden elevation and subsequent fall of serum creatine phosphokinase (CPK) 
levels with or without myoglobinuria. There is no consensus concerning the exact level of CPK rise 
required to fulfil the definition of RM, with suggested CPK levels ranging from > 5, > 10, > 20 to even 
> 50 times the upper limit of normal (ULN) [9]. ERM is defined as RM preceded by triggering 
strenuous exercise (often under environmental conditions at the extremes of the temperature scale). 
RM results in the entry of skeletal muscle contents, in particular CPK and myoglobin, into the 
systemic circulation. The course is mostly characterized by myalgia with mild to moderate CPK 
increases, mild asymptomatic pigmenturia, and will often not even come to medical attention. 
However, in a minority of patients the clinical course is severe, resulting in profound hyperCKaemia, 
acute renal failure, compartment syndrome, disseminated intravascular coagulation, cardiac 
arrhythmias secondary to electrolyte imbalances, and even cardiac arrest if left untreated. The 
degree of metabolic disturbances and the severity of RM-related clinical features depends on the 
amount of muscle damaged and various endogenous and exogenous factors (such as hypovolemia, 
hypotension, body temperature, sepsis, intake of toxic drugs, general health, hormone environment 
and genetic susceptibility). Irrespective of its cause, the pathophysiological events in RM follow a 
common pathway, summarized in Box 1. The annual RM prevalence has been reported as 26,000 
cases in the United States, with 47% meeting the diagnostic criteria of ERM [10]. 
Box 1: Pathophysiology of exertional rhabdomyolysis (ERM) 
Normally, ion pumps and channels in the sarcolemma maintain a low intracellular Na+ and Ca2+ and 
a high intracellular K+ concentration. Unaccustomed (eccentric) exercise may cause direct injury to 
the sarcolemma and/or lead to failure of energy production with subsequent pump dysfunction of 
Na+/K+ATPase and Ca2+ATPase. This leads to increased cellular permeability to sodium ions and, 
consequently, increased intracellular calcium concentrations, with subsequent muscle contraction 
increasing the energy deficit. This also enhances the activation of calcium-dependent proteases and 
phospholipases, which contributes to destruction of myofibrillar, cytoskeletal and membrane 
proteins. Subsequently, large quantities of intracellular electrolytes, metabolites as well as 
intracellular proteins (aldolase, myoglobin, CK, lactate dehydrogenase, aspartate transaminase) leak 
into the circulation. The resulting free calcium will add to the contraction of the already over-
activated myocytes. 
Electrolyte disturbances normally occurring during exercise, e.g. hypokalemia (through perspiration) 
and hyponatremia (due to polydipsia) reinforce this process. Potassium release from muscle cells 
during exercise normally mediates vasodilation and an appropriately increased muscle blood supply. 
Hence, hypokalemia may promote the development of RM by decreasing blood flow to muscles in 
response to exertion, thus limiting availability of energy sources. Next, potassium leak from 
myocytes into the bloodstream causes hyperkalemia, which can result in fatal cardiac arrhythmias. 
Hyponatremia contributes to Na+/Ca2+-ATPase dysfunction, which leads to the activation of 
proteases and lipases that are responsible for further cell lysis. Furthermore, hyponatremia causes 
failure of cell volume regulation. Combined with other cellular responses to exercise such as 
increased oxidative stress and release of pro-inflammatory cytokines, this will ultimately result in 
cell death and intracellular components spilling into the surrounding tissue. This is perpetuated by 
extreme ambient temperatures. The prolonged exposure to very low temperature causes 
vasoconstriction and subsequent cell damage. On the other hand, hyperthermia is considered as a 
hypermetabolic condition that triggers RM when the energy supplies are not adequate in relation to 
cellular requirements.  
 
RM often represents a “physiological” response to extreme external triggers, such as fasting, viral 
infections, toxins or medication, strenuous physical exercise, exercise under extreme circumstances, 
or a combination of these factors [11]. In contrast, ERM might also be the first manifestation of a 
genetic muscle disorder, reflective of the potential of such conditions to lower the trigger threshold 
for developing muscle breakdown. A genetic cause should always be considered in case of recurrent, 
familial or paediatric episodes of ERM presenting very early in life; if such episodes are associated 
with other (exercise-induced) muscle symptoms such as cramps, myalgia, exercise intolerance, 
hyperCKemia in the personal or family history, or if the severity of RM exceeds the expected 
response to the exercise. The recognition of a patient with an underlying genetic disorder is essential 
for the acute management but also (and most importantly) for counselling afterwards. Several 
genetic disorders increase the risk of developing RM. These include metabolic myopathies, disorders 
of calcium homeostasis, various muscular dystrophies (particular limb girdle muscular dystrophies 
such as LGMD2I and milder dystrophinopathies), and the sickle cell trait. We refer to recent detailed 
reviews for an overview of genetic disorders to be considered where the nature of the RM episodes 
raises the suspicion of such a condition [12-14]. 
3. RYR1-related (exertional) rhabdomyolysis ((E)RM) 
A link between ERM and MHS had been suggested since the original description of the latter but until 
recently had only been documented in case reports and small series. Such a link is plausible, 
considering 1) an uncontrolled rise in intracellular skeletal muscle calcium as the most important 
shared pathomechanism [15]; and 2) the common occurrence of MH and ERM in a number of 
porcine [16], equine [17] and murine [18, 19] RYR1 mutants. 
Wappler et al. were the first to perform a contracture test (the standard diagnostic test for MH since 
the mid 1970-s, consisting of the in vitro measurement of contracture response of biopsied muscle to 
graded concentrations of caffeine and halothane; it is referred to as the caffeine/halothane 
contracture test (CHCT) in North America and the in vitro contracture test (IVCT) in Europe) in 12 
unrelated patients with ERM in 2001, ten of which had positive results; one patient had a negative 
test result, and one patient showed equivocal responses [20]. Three of these patients had RYR1 
mutations but only hot-spots sequencing had been performed at the time [20]. Based on their 
findings, the authors recommend performing genetic testing for MH-associated RYR1 mutations, 
muscle biopsies for histological examination and IVCT in patients presenting with ERM. In 2009, 
Sambuughin sequenced the RYR1 gene in six unrelated African-American men with unexplained ERM, 
who were subsequently diagnosed as MHS on CHCT. Three novel mutations and two variants 
previously reported in Caucasian MH-Susceptible subjects were found in five patients studied, 
further emphasizing the importance of performing CHCT and RYR1 mutation screening in patients 
with unexplained ERM [21]. In our seminal study systematically investigating a possible link between 
ERM and RYR1 mutations in 2013, RYR1 was sequenced in 39 unrelated families with RM, in whom 
common metabolic and mitochondrial causes had been excluded [8]. In this series we identified nine 
heterozygous RYR1 mutations/variants in 14 families, five of them (K1393R; G434R; 
T4288_A4290dup; A4295V; and R4737Q) previously associated with MH. Index cases presented from 
3 to 45 years with RM with or without exertional myalgia (n=12) or isolated exertional myalgia (n=2). 
Familial RYR1 mutations were confirmed in relatives with similar, exertional myalgia without RM, or 
no symptoms. Common triggers were exercise and heat and, less frequently, viral infections, alcohol 
and drugs. Most subjects were normally strong and had no personal MH history. Some reported heat 
intolerance and cold-induced muscle stiffness. Muscle biopsies showed mainly subtle changes. These 
findings suggest that RYR1 mutations account for a substantial proportion of patients presenting with 
unexplained RM and/or exertional myalgia, in particular in association with the reported triggers. 
Associated features may be subtle, including prior exertional myalgia, mild hyperCKemia, mild axial 
weakness or subtle (unilateral) ptosis, and some degree of unevenness of oxidative staining on 
muscle biopsy. Family counselling is vital to identify potentially MH-susceptible relatives [1]  
We performed a systematic literature review (including the patients in the studies mentioned 
above), based on a Pubmed search with “RYR1” and “rhabdomyolysis”. This resulted in identification 
of several case report and small series [1, 8, 21-26], and two review article [27, 28] Subsequently, we 
also included cases from references of these articles [20, 26, 29-34] and added our recent letter by 
Snoeck et al. [35]. Finally, we added two patients from our paper on the spectrum of RYR1 related 
myopathies by Snoeck et al. who were not included in any other publication (patients 14 and 52[1]). 
We excluded the patients who suffered only from exertional myalgia without clinical or biochemical 
RM (Family 11 and 14 in Dlamini et al.[8]). We identified 37 patients with non-anaesthetic RM due to 
RYR1 mutation(s) (age range 1 – 64 years; 31 males and 6 females). The most important features 
from these cases are summarized in Table 1, and an illustrative case reported recently is presented in 
more detail in Box 2 [35]. 
Box 2: RYR1-related exertional rhabdomyolysis (ERM) in a 16-year old patient – case study 
This patient is a currently 21-year-old semi-professional male cyclist who has experienced three 
episodes of RM after cycling [35]. The first episode occurred at the age of 14, when he developed 
profound myalgia in his legs four days after a race, resulting in impaired walking. He recovered 
within one week and continued with cycling training without seeking medical advice. When he had 
the same symptoms two years later, his CPK was found to be elevated at 29,914 IU/l and he was 
admitted to the ICU for rehydration. He was referred at the age of 17. He reported that the race 
where the ERM episode occurred had taken place in very cold weather, but that he had competed 
under similar conditions before. Most likely, the combination of several triggers (use of NSAIDs 
because of mild flu-like symptoms before the race; very cold temperature; strenuous training 
preceding the race; and use of a caffeine gel as an energy booster) had caused the ERM episode 
after this particular race. Physical examination revealed an athletic build but mild weakness of the 
rhomboid muscle (MRC 4)(Figure 3). He also had mild bilateral ptosis. The muscle biopsy (including 
EM) showed an increase of internal nuclei but no cores. RYR1 sequencing revealed compound 
heterozygous RYR1 mutations, I2321V (maternal allel) and V4849I (paternal allel) previously 
associated with MH. The IVCT was positive, confirming MHS. After he was diagnosed with RYR1-
related ERM, he adapted his training regime and refrained from use of caffeine and NSAIDs. 
Nevertheless, at the age of 18 he experienced a third ERM episode with severe myalgia and 
significant hyperCKaemia (10,820 IU/l), and he subsequently gave up semi-professional cycling. 
His father carried the G14545A mutation and was also very athletic but never experienced similar 
problems. However, his paternal uncle (G14545A carrier) had visited our centre at the age of 37 
because of hyperCKemia, fatigue and muscle cramps. He was also very athletic (regular cycling, 
rugby) and had experienced exertional myalgia and muscle stiffness since the age of 35. CPK levels 
were around 800 IU/l. The muscle biopsy had shown mild non-specfic myopathic features (increase 
in fibre size variability and internal nuclei but no cores). Physical examination at the age of 49 
showed an athletic build, no muscle weakness but a mild ptosis (Figure 3). After genetic testing 
confirmed the G14545A mutation, he was counselled for the MHS risk and referred to the 
rehabilitation specialist for training advice. All first degree relatives were screened for the G14545 
mutation because of the MHS risk. 
 
The review of these cases revealed very important insights into the characteristic features of RYR1-
related RM. First, RM manifested at all ages, with a fatal non-anaesthetic MH reactions in six 
children. There was a male predominance (84%). In many cases, RM was not provoked by the first 
exposition to a specific trigger and often a combination of variable triggers (including recreational 
and medical drugs) was present, both in children and adults, e.g. physical exercise and hot ambient 
temperatures, or viral infection or exercise and medication. Gener et al. reported the case of a child 
who had suffered a sevoflurane-triggered MH episode treated with dantrolene during an 
orchidopexy procedure (at the age of 3 years 5 months), a common operation during which MH 
episodes have been observed [32]. He died at the age of 5 and a half years when he developed 
muscle rigidity and became hyperthermic and asystolic after receiving ondansetron because of 
vomiting and abdominal pain [32]. A recent case published by Russell et al. illustrates a similar point: 
a 20-year-old woman who developed RM, disseminated intravascular coagulopathy and multi-organ 
failure induced by MDMA. Following initial improvement, she developed delayed RM due to 
haloperidol-induced neuroleptic malignant syndrome (NMS), which was treated with dantrolene. 
Subsequent genetic testing revealed a novel potentially pathogenic variant in RYR1 (G2545A). The 
case reported by Lavezzi showed how succinylcholine augmented the hypermetabolic state resulting 
from heat stroke, leading to subsequent death [33]. Furthermore, Forrest reported an MH event 
preceded by unaccustomed exercise, suggesting that MH may in fact also be a multifactorial event 
and providing a potential explanation for its highly variable penetrance [36].  
These observations support the suspected relationship between exertional heat illnesses, ERM, and 
MHS (Box 3) [15, 25], with a fatal course especially in children illustrated in several reports. Nishio et 
al. presented a young patient (2 years 9 months) that died of heat stroke after being left in a car in 
high environmental temperature. Postmortem mutation analysis revealed that the child carried 
compound heterozygous RYR1 mutations L4320_R4322dup and R4645Q. Since each mutation had 
previously been documented to cause MHS on its own, a non-anaesthetic MH-like response 
prompted by high environmental high temperature might have occurred in this child essentially 
carrying a “double-dose” of MHS-related RYR1 mutations [30]. Groom et al. reported a de novo RYR1 
variant (R3983C) in two unrelated children who experienced fatal, non-anesthetic MH episodes 
associated with febrile illness and heat stress. One of those children had numerous episodes of leg 
cramping, tachycardia, tachypnea and increased creatinine kinase years before the fatal episode [29]. 
Tobin reported a 13-year old patient who died of a stress-induced hyperpyrexic death without 
anaesthetic exposure after a football game with an ambient temperature of 26°C. One and a half 
year prior, he had developed an MH response to general anaesthesia, for which he was successfully 
treated with dantrolene. Post mortem RYR1 sequencing revealed a RYR1 mutation (R163C) in the 
patient and, on further testing, in his father [31]. The children reported by Gener and Lavezzi also 
had a fatal outcome of their heat illness.[32, 33] This clinical overlap has implications for some MH-
susceptible patients and their capacity to exercise, as well as for clinicians treating and anesthetizing 
patients with histories of unexplained exertional heat and exercise illnesses [25]. 
 
Box 3: Exertional heat illness, exertional rhabdomyolysis (ERM), and malignant hyperthermia 
susceptibility (MHS) [15, 25, 37] 
Exertional heat illness, ERM, and MH have similar pathophysiology: all three are hypermetabolic 
states that include high demand for adenosine triphosphate, accelerated oxidative, chemical, and 
mechanical stress of muscle, and uncontrolled increase in intracellular calcium. 
Heat related illnesses: 
1. Heat stroke: a severe condition of hyperthermia (body temperature > 40.6 °C (105.1 °F)) due 
to environmental heat exposure with lack of thermoregulation. The term "stroke" in "heat 
stroke" refers to the altered mental status that accompanies this hypermetabolic condition. 
Prevention consists of drinking plenty of cool liquids and avoiding excessive heat and humidity, 
especially in unventilated spaces. Treatment requires rapid physical cooling of the body. 
2. Heat exhaustion: a condition of heavy sweating and tachycardia, resulting in dehydration, 
salt-depletion, and hypovolaemia. Causes include exposure to high temperatures, particularly 
when combined with high humidity, and strenuous physical activity. Without prompt treatment, 
heat exhaustion can lead to heatstroke. 
3. Heat syncope: fainting due to peripheral vasodilatation secondary to high ambient 
temperature. It occurs with or without mental confusion. 
4. Heat cramps: Painful, brief muscle cramps that occur during exercise or work in a hot 
environment or begin a few hours later. They are likely to be related to electrolyte problems due 
to extensive sweating and rehydration with large amounts of water or other fluids that lack salt. 
 
Exertional rhabdomyolysis (ERM): the breakdown of muscle from extreme physical exertion. It is a 
common complication of exertional heat illness, but may also occur in the absence of features of 
exertional heat illness. There is a clear association with RYR1 variants, including variants associated 
with MH susceptibility. Risk factors: strenuous exercise under high temperatures and humidity; poor 
hydration; inadequate recovery between exercise, inadequate fitness levels. 
 
Malignant hyperthermia (MH): a rare life-threatening condition that is characterized by rapid rise of 
end-tidal CO2 and body temperature occuring in susceptible individuals who receive volatile 
anesthetic agents and/or succinylcholine. In susceptible individuals, these drugs can induce a drastic 
and uncontrolled increase in oxidative metabolism as a result of a persistent intracellular Ca2+, which 
devastate the capacity to supply oxygen, remove carbon dioxide, and regulate body temperature, 
eventually leading to circulatory collapse and death if not immediately treated.  
 
These latter cases also point to the muscular symptoms that were present prior to the RM episode 
in many of the index cases. More than half of the patients we identified through our literature search 
reported prior exertional myalgia (Table 1). Two of the three families reported by Davis et al. also 
reported intermittent muscle pain and cramps, often precipitated by exercise. These episodes lasted 
for two weeks and were so severe that walking was impaired [26]. Finally, muscle biopsy showed 
signs of a congenital myopathy in only one patient and one carrier father; all other biopsies were 
normal or showed only aspecific changes. 
Several reports show that muscular symptoms might also occur in other relatives compatible with 
an autosomal dominant inheritance pattern. For example, Potts et al reported a 30-year-old man 
with persistent hyperCKemia, severe debilitating muscle cramps, and unexplained RM. The CHCT was 
positive, and subsequent RYR1 sequencing revealed a mutation functionally causative for MH. His 
identical twin brother, who was suffering from similar complaints, was found to share the same 
mutation. It is important that such features are specifically asked for in the family history, as patients 
and their relatives may not necessarily consider those symptoms linked. The dominant inheritance 
differentiates this cause from metabolic causes of RM (in particular disorders of glycogen 
metabolism, disorders of long-chain fatty acid metabolism and mitochondrial myopathies; for 
review: [12-14]). Another distinguishing feature from the metabolic myopathies is that fasting was 
not a trigger in any of the RYR1-related cases. For example, a previously reported 44-year-old patient 
with recurrent, severe episodes of fever-induced RM (521,500 IU/L) had been exposed to several 
prolonged periods of religiously motivated fasting without experiencing any symptoms [23]. 
The case reported by Capacchione et al. illustrates that symptoms increase in the course of several 
days after the strenuous exercise [25]. This was also reported by the young cyclist in Box 2: in both 
episodes, the myalgia manifested three to four days after the race. This timeline is similar to the 
development of myalgia after unaccustomed exercise in healthy individuals, and parallels the CPK 
increase (Figure 2). Heat-induced RM generally develops more rapidly, which likely results from acid-
base and plasma composition changes. The initial lactic acidosis and respiratory alkalosis evolves into 
a predominantly metabolic acidosis, reflecting tissue damage (release of sulphate, phosphate and 
organic acids).  
Finally, individuals with RYR1-related RM are often particularly muscular and athletic, making life 
style advice after a RM event more challenging. One of the patients reported by Dlamini et al. 
(patient 7.II.2;also patient 23 in Snoeck et al.) had to change her plans to become a sports coach after 
the second ERM episode with CPK levels up to 378,900 IU/l [1, 8]. Similarly, the patient illustrated 
above (Box 1) stopped cycling semi-professionally only after another episode of RM requiring 
hospital admission occurred a year after he was diagnosed with RYR1-related RM. 
As a complicating factor, counselling might be challenging in cases with more than one RYR1 
mutation, especially where the pathogenicity of individual mutations is not defined yet. In the cohort 
we identified, nine patients had more than one mutation (Table 1). Another complicating factor in 
counselling is the often highly variable penetrance of the familial RYR1 mutation. The father of the 
patient in box 2 also carried the RYR1 mutation and was very active in sports, but never experienced 
any RM episodes.[35] Even more remarkable is the carrier brother of patient 7.II.2 reported in 
Dlamini et al. (Figure 1 in that article), who is very active in weightlifting competition but never had 
any RM episodes [8]. 
A particular complex issue is the variable relationship between RYR1-related RM and the results of 
CHCT or IVCT testing. The mother of the patient reported by Russell [24] and two patients reported 
by Snoeck et al. (patient 29 and 52)[1], all with one or more episodes of RM, had negative results on 
the CHCT or IVCT, proving a lack of complete overlap between ERM and MHS. This test, which 
remains the only validated diagnostic test for phenotypical MHS, has several limitations. It was 
validated by comparing muscle biopsy tissue from patients with documented histories of anesthesia-
related MH to muscle biopsy tissue from control patients resulting in a specificity of 93,6% and a 
sensitivity of 99% [38]. As a result, using the CHCT or IVCT to diagnose people as MHS who present 
with (E)RM, given that these tests were not developed or validated to evaluate these patients, might 
give false-positive results. In the three patients with negative tests, pathogenicity was assumed 
based on the presence of biallellic mutations (patient 52), the absence of the mutation in normal 
population, and/or the results of in silico analysis. Functional testing of the mutant RyR1 channels in 
a suitable expression system will be required to confirm the pathogenicity of mutations where CHCT 
or IVCT testing is equivocal or negative. 
The case reported by Lavezzi et al illustrates the importance of recognizing RYR1-related heat 
illness: this healthy 6-year-old boy developed lower extremity rigidity, trismus, and fever after 
playing in an inflatable swimming pool. On arrival in the emergency department, he appeared to be 
seizing. An endotracheal tube was urgently placed using succinylcholine to facilitate muscle 
relaxation, he went into cardiac arrest and resuscitation attempts were unsuccessful. Post mortem 
genetic analysis showed a novel RYR1 variant, also confirmed in his father who had a positive CHCT 
response and central cores on the muscle biopsy [33]. This case, and that of Capacchione [25] 
exemplify that (E)RM is a presentation of RYR1-related myopathies most anaesthesiologists are not 
familiar with [25, 33]. Furthermore, most general practitioners, emergency department physicians, 
hospital doctors, and intensivists do not associate (E)RM with MH; thus, consideration of RYR1 
mutations as a cause may be easily forgotten. Although the incidence of fulminant MH during 
anaesthesia is relatively rare (with estimates between 1 in 4200 to 250,000), the incidence of RYR1 
mutations with MHS in the general population might be up to 1 in 2000 [5]. This implies that there is 
a cohort of possible MH-Susceptible individuals who do never develop MH during general 
anaesthesia but may well present with ERM at one point in life. In support of this point, exome 
sequencing performed on 870 volunteers without medical or family histories for MHS identified 
three RYR1 variants predicted to predispose to MH reactions.[39] 
Finally, the case reported by Potts et al illustrate the continuous use of dantrolene for treatment of 
cramps and prevention of RM: these 30-year-old identical twin brothers with persistent 
hyperCKemia, severe debilitating muscle cramps, and unexplained RM both required oral dantrolene 
therapy to control their symptoms [34]. 
 
Pathophysiology. The precise pathophysiological mechanism(s) underlying human RYR1-related 
(E)RM are still unknown but investigations in relevant animal models may provide useful information: 
studies in the Y522S RyR1 KI mouse (a murine model of human MH) suffering RM and death in 
response to elevated environmental temperatures suggest a complex interplay and a vicious cycle 
involving the primary RyR1 defect and secondary metabolic RyR1 modifications: The murine Y522S 
RyR1 was shown to cause a Ca2+ leak, which drives increased generation of reactive nitrogen species; 
the resulting S-nitrosylation of the mutant RyR1 receptor in turn further increases its temperature 
sensitivity, lowering the threshold for producing muscle contractures upon exposure to elevated 
temperatures. Many mitochondria in the muscle of heterozygous Y522S mice are swollen and 
misshapen, and the mutants display force reduction with aging. Assuming that mitochondria as a 
store of Ca2+ play a buffering role in controlling cytosolic Ca2+ metabolism under normal conditions, 
the authors propose a destructive feed-forward cyclic mechanism that increases the temperature 
sensitivity of RyR1 activation and underlies heat stroke and sudden death. They propose that this 
cycle eventually produces a myopathy with damaged mitochondria due to defects of the 
mitochondrial respiratory chain (Figure 4)[19]. The overall increase in RyR1 sensitivity to activation by 
stimuli that promote Ca2+ release render the muscle more susceptible to rhabdomyolysis to the 
presence of any trigger, among which is (eccentric) strenuous exercise.[18] 
 
4. Management 
Acute management. The first step when encountering a patient with a (E)RMis to determine whether 
the RM is clinically significant, requiring hospital admission and intravenous fluid administration. 
Although randomized controlled trials offering concrete management guidelines for these aspects of 
RM management do not exist, the study by Kenney at al. reporting a large cohort of representative 
cases with physiological ERM offers some practical guidelines at least for the initial steps 
(summarized in Box 4 and [9]). 
Box 4: Features requiring hospital admission and intravenous fluid administration 
Clinical features  Myalgia with: 
 muscle weakness 
 swelling 
 altered consciousness 
Exercise  Accustomed / unaccustomed 
History In patient or relatives: 
 prior episodes of ER 
 other indicators of NMD 
 renal, cardiac or co-morbidity 
Vital signs Abnormal  
Body temperature > 40°C (heat stroke) 
CPK (U/l) ≥ 10,000 
Myoglobinuria/myoglobinemia  Present 
Acute renal failure  Absent or present 
Electrolyte abnormalities Absent or present 
Acid base status Abnormal 
Other factors possibly provoking RM  Absent or present 
 
The goals of both inpatient and/or outpatient treatment are to avoid renal injury, prevent further 
muscle injury, and to limit complications resulting from electrolyte disturbances; this is summarized 
in Box 5. Most importantly, in RYR1-related ERM cases, the specific RyR1 antagonist dantrolene can 
be administered to limit further muscle breakdown and CPK increases, and more severe, potentially 
life-threatening downstream medical complications. In addition, allopurinol has recently been 
suggested as a treatment for exercise-induced muscle damage [40]. Allopurinol is a purine 
hypoxanthine-based structural analogue and a well-known inhibitor of xanthine oxidase, an enzyme 
which generates free radicals during oxidative stress induced by intensive muscular activity. Its 
administration may hence be regarded as promising, safe, and an economic strategy to decrease 
transient skeletal muscle damage and limit RM. 
Box 5: Management of exertional rhabdomyolysis (ERM) [41, 42] 
Out-patient follow-up of patients with physiological exertional rhabdomyolysis (ERM) 
Rest for 72 h and encourage oral hydration 
Sleep 8 h consecutively, nightly 
Prevent heat exposure: Remain in thermally controlled environment if ERM occurred in 
association with heat injury.  
Refer to ER in case temperature exceeds 40 °C 
Follow up in 72 h for repeat CPK and blood urea:  
 CPK < 5 x ULN and normal blood urea: no further studies 
 Return every 72 h and repeat until CPK < 5 x ULN and normal blood urea 
 CPK ≥ 5 x ULN or abnormal blood urea for > 2 weeks: refer for expert consultation 
 CPK ≥ 50 x ULN (10,000 U/l): refer to ER again 
Refrain from sports 
Elimination of medications, drugs and toxins that are considered to cause RM 
Clinical management of patients with clinically significant RM  
Administration of oral or iv dantrolene (dose dependent on severity of RM and hypermetabolic 
state) 
Hyperhydration: Intravenous fluids should be initiated as soon as possible, preferably within the 
first 6 hours after muscle injury, at a rate that maintains a urine output in adults of ≥ 300 mL/h for 
at least the first 24 hours 
Admittance to ICU 
Peritoneal dialysis or hemodialysis in patients with little or no urine output despite 
hyperhydration, profound acidosis, or severe hyperkalemia 
Mannitol should be administered only to maintain urine output of 300 mL/h or more despite 
adequate fluid administration 
Sodium bicarbonate should be administered only if necessary to correct systemic acidosis 
Elimination of medications, drugs and toxins that are considered to cause RM 
 
Low dose oral dantrolene could also be considered for the treatment of chronic muscle pain and 
prevention of recurrent episodes in individuals with MHS or RYR1-related RM without significantly 
affecting performance [44]. 
 
Restarting sports. Patients with RYR1-related ERM will have a higher recurrence risk and will have to 
be specifically advised with regards to subsequent sporting activities. If such patients choose to 
continue with exercise, they should be advised to try to avoid exercising at times of extreme 
environmental temperatures, during intercurrent (febrile) illness and/or when medical or 
recreational drugs are being taken. O’Connor suggests three phases of return to physical exercise for 
athletes who are not at risk: Phase I: onset to normalisation of CPK to < five times upper limit of 
normal; Phase II: start of light activities; Phase III: Gradually return to regular sporting activities and 
physical training (Guideline evolved from the Rhabdomyolysis working group at the Consortium for 
Health and Military Performance (CHAMP): Box 6) [43]. Patients with RYR1-related RM may also be at 
risk of MHS with important consequences for affected individuals and their relatives carrying the 
same RYR1 variants.  
Box 6: How to restart sports? [43]  
First four weeks (Phase I) 
 Begin light but no strenuous physical activities 
 Follow up with physician in 1 wk 
 In case of clinical symptoms (muscle weakness, swelling or myalgia) return to physician 
 Remain in start schedule and return at 1-wk intervals 
Advice to restart sport at least four weeks after the event and only if the patient is 
asymptomatic (Phase II -III: 
 Only if no clinical symptom return (muscle weakness, swelling or myalgia) gradually increase 
the intensity and duration 
 Avoid unaccustomed exercise, especially eccentric training 
 Follow up with care provider as needed 
Additional advices: 
 Very gradual return to a less intense training schedule 
 Search help of a physical therapist / sports medicine specialist / rehabilitation specialist with 
expertise of training in inherited myopathies 
 Strictly avoid the combination of strenuous exercise with other risk factors for RM (drugs, 
medication, supplements, viral infection) 
 Strictly avoid unaccustomed, strenuous exercise, especially eccentric training 
 Prevent dehydration during exercise 
 Prevent the combination of extreme heat and cold exposure and exercise: limit training 
intensity in hot and humid environment, and in very cold environments 
 Report to physician in case of exertional myalgia and perform CPK check-up 
 Do not use caffeine or other supplements 
 Limit alcohol consumption in periods of intense sport activities 
 Wear a SOS necklace 
 
5. Concluding remarks 
This review has focused on the specific features of RYR1-related (E)RM, a probably not uncommon 
but underdiagnosed form of RM. Various triggers, alone or in combination, can evoke RYR1-related 
RM, including physical exercise, especially if unaccustomed and/or performed under extreme 
environmental temperatures, viral infection, and medical and recreational drugs. These are in fact 
the same triggers known to evoke RM in general, but in the context RYR1 mutations, the trigger 
threshold is lower, or RM events are more severe and/or recurrent. In contrast to some of the 
metabolic causes, inheritance is mainly dominant, myalgia generally does not occur during but 
following often considerable intervals (up to 72 hours) after exercise, and fasting has not been 
reported as a triggering factor. Patients may often be particular muscular and athletic, making 
lifestyle advice difficult. Individuals with RYR1-related RM may also be MH-susceptible, but the 
relationship with CHCT or IVCT results is not consistent, suggesting an area for further research. 
Recognition of RYR1 mutations as a cause of rhabdomyolysis is vital for effective (family) counselling, 
to identify potentially MH-susceptible individuals and to adapt training regimes. Studies in various 
animal models may provide insights into pathophysiological mechanism(s) of potential relevance also 
for humans, and offer therapeutic perspectives.  
Figures 
Figure 1: Spectrum of inherited myopathies and muscular conditions due to RYR1 mutations in Dutch 
cohort (Reprinted with permission of the publisher (N=77)[1]. 
 
Figure 2: Temporal course of myoglobin and CPK levels during a typical rhabdomyolysis (RM) 
episode. Myoglobin is the first enzyme that increases, but returns to normal levels within the first 24 
hours after onset of symptoms. CPK increases a few hours later, reaches its peak value within the 
first 24 hours, and remains at these levels for around 3 days. Even though the presence of myoglobin 
in serum is the key feature of RM, CPK is considered to be a more useful marker for the diagnosis and 
assessment of the severity of muscle injury due to its delayed plasma clearance and the wider 
availability for diagnostic testing. 
[Reprinted from European Journal of Internal Medicine, Vol. 18, issue 2. Giannoglou, Chatzizisis, 
Misirli. The syndrome of rhabdomyolysis: pathophysiology and diagnosis. Pages 90-100. Copyright 
2007, with permission from Elsevier]. 
 
Figure 3: A 17-year old semi-professional cyclist with a history of recurrent RYR1-related ERM 
episodes. Note mild axial weakness. A paternal uncle carrying the same mutation had presented with 
exertional myalgia earlier in life, and was found to have an athletic build and mild unilateral ptosis on 
examination. 
 
Figure 4: Possible pathophysiology of RYR1-related rhabdomyolysis, based on the model of 
exertional/environmental Heat Stress and Myopathy in RyR1Y522S/wt Mice [19]: 
1) In case of MHS-related RYR1 mutatons, RyR1 channels are more sensitive and open more readily 
to voltage, ligand, and Ca2+ activation, causing a Ca2+ leak and small, possibly local increases in resting 
[Ca2+]; 2) Increased cytosolic [Ca2+] levels stimulates production of reactive nitrogen species 
generation (RNS) and 3) subsequent increased RyR1 S-nitrosylation, which; 4) in turn increases RyR1 
temperature sensitivity. S-nitrosylation also decreases RyR1 sensitivity to Ca2+ inhibition further 
promoting SR Ca2+ leak; this results in 5) additional Ca2+ increases and further enhance ROS/RNS 
production, leading to a vicious feed-forward cycle mechanism. Finally, chronically elevated levels of 
Ca2+ and ROS/RNS damage mitochondria and contribute to the development of myopathy. 6) In case 
of heat stress – due to exercise in hot environments - Ca2+ release from the modified RyR receptors is 
greatly and persistently augmented, eventually leading to heat stroke. [19] In addition, viral infection 
and (medical and / or recreational drugs) may reinforce this feed-forward cycle mechanism. 
 
Table 1: Overview of RYR1 mutations associated with non-aesthetic rhabdomyolysis (RM) reported in 
the literature.  
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Table 1 
Sex: m = male; f = female 
Race: A = African; AA = African-American; C = Caucasian; AC = Afro-Caribbean 
Mutation(s): amino acid changes unless otherwhise specified 
Triggers: E = exercise; H = heat; I = infection; D = drugs; 1 MDMA, haloperidol; 2 simvastatin; 3 alcohol; 4 caffeine gel; 5 olanzapine; 6 succinylcholine 
CHCT: caffeine halothane contraction test / IVCT: in vitro contracture test (in patient or in one of the related RYR1 mutation carriers; ND: not determined (mostly in cases in 
which previously reported mutations were detected) 
Muscle biopsy: MmD = Multi-minicore Disease; CCD = Central Core Disease; OS = oxidative staining 
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